niacinamide has been researched along with losartan potassium in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chong, ZZ; Hou, J; Maiese, K; Shang, YC | 1 |
| Hashimoto, Y; Iizuka, J; Ishimori, I; Kennoki, T; Kimata, N; Kobayashi, H; Kondo, T; Murakami, J; Nakazawa, H; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| Chong, ZZ; Maiese, K; Shang, YC; Wang, S | 1 |
| Agarwal, KL; Bakris, GL; Bhatta, SS; Cohen, EE; Karrison, T; Maitland, ML; Ratain, MJ; Seiwert, TY; Sit, L; Vokes, EE; Wroblewski, KE | 1 |
1 review(s) available for niacinamide and losartan potassium
| Article | Year |
|---|---|
Novel directions for diabetes mellitus drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Delivery Systems; Drug Discovery; Erythropoietin; Humans; Hypoglycemic Agents; Niacinamide; Signal Transduction; TOR Serine-Threonine Kinases | 2013 |
3 other study(ies) available for niacinamide and losartan potassium
| Article | Year |
|---|---|
Diabetes mellitus: channeling care through cellular discovery.
Topics: Animals; Cell Cycle; Cell Survival; Diabetes Mellitus; Erythropoietin; Forkhead Transcription Factors; Humans; Niacinamide; Oxidative Stress; Proto-Oncogene Proteins c-akt; Signal Transduction; Wnt Proteins | 2010 |
Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Erythropoietin; Feasibility Studies; Hematinics; Hemoglobins; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Renal Dialysis; Sample Size; Sorafenib; Treatment Outcome | 2011 |
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
Topics: Axitinib; Blood Pressure; Clinical Trials as Topic; Combined Modality Therapy; Erythrocyte Count; Erythropoiesis; Erythropoietin; Fluorouracil; Humans; Imidazoles; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |